In This Section

Program

Please note that this symposium will take place as an in-person event in Montreal and will not live-stream content for virtual participation. The symposium content will be recorded and made available as an on-demand program after the symposium. Please visit the registration page for details.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Monday, June 10

Tuesday, June 11

Wednesday, June 12

Thursday, June 13

Monday, June 10

welcome and introductions
6-6:05 P.M.

  • Michael A. Erb, The Scripps Research Institute, La Jolla, California
  • Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
  • E. Alejandro Sweet-Cordero, University of California, San Francisco, California
  • Kris C. Wood, Duke University School of Medicine, Durham, North Carolina

Opening Plenary
6-7 P.M.
CME-Eligible

  • Scientific Keynote
    Exploiting pathway activation as a new form of synthetic lethality
    William R. Sellers, Broad Institute and Dana-Farber Cancer Institute, Cambridge, Massachusetts 

OPENING RECEPTION
7-8:30 P.M.

Tuesday, June 11

CONTINENTAL BREAKFAST
7-8 A.M.

PLENARY SESSION 1: Chemical Biology Tools to Advance Synthetic Lethality
8-10 a.m.
CME-Eligible

Session Chair: Fleur M. Ferguson, UC San Diego, La Jolla, California

  • Exploiting metabolic vulnerabilities in PDAC to overcome K-Ras inhibitor resistance
    Fleur M. Ferguson, UC San Diego, La Jolla, California
  • Chemoproteomic discovery of a synthetic lethal allosteric inhibitor of WRN helicase
    Matthew P. Patricelli, Vividion Therapeutics, San Diego, California
  • Redirecting FOXA1 pioneering function with covalent small molecules 
    Michael A. Erb, The Scripps Research Institute, La Jolla, California
  • KIF18A inhibition, via ATX020, leads to mitotic arrest and robust anti-tumor activity through a synthetic lethal interaction with chromosome instability* 
    Maureen Lynes, Accent Therapeutics, Lexington, Massachusetts
  • Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer* 
    Yonghao Yu, Columbia University Vagelos College of Physicians and Surgeons, New York, New York 

BREAK
10-10:30 A.M.

PLENARY SESSION 2: Mechanisms of Synthetic Lethality
10:30 A.M.-12:30 P.M.
CME-Eligible

Session Chair: Zuzana Tothova, Dana-Farber Cancer Institute, Boston, Massachusetts 

  • Therapeutic vulnerabilities of cohesin-mutant myeloid malignancies 
    Zuzana Tothova
  • Synthetic vulnerabilities in cancers driven by chromatin remodeler mutations
    Charles W.M. Roberts, St. Jude Children’s Research Hospital, Memphis, Tennessee 
  • The long isoform  of RAP1GDS1 is a synthetic vulnerability in RAS-driven lung adenocarcinoma
    E. Alejandro Sweet-Cordero, University of California San Francisco, San Francisco, California 
  • Mechanisms of therapeutic vulnerability of mismatch repair defective cancers to RNA polymerase I inhibitors* 
    Marikki Laiho, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 
  • Computational discovery of paralog dependencies drives target identification in lung cancer* 
    Siobhan O’Brien, Fred Hutchinson Cancer Center, Seattle, Washington 

LUNCH (ON OWN)
12:30-2:30 P.M.

Plenary Session 3: Clinical Translation of DNA Damage Synthetic Lethality
2:30-4:30 P.M.
CME-Eligible

Session Chair: Michael A. White, Ideaya Biosciences, San Diego, California 

  • Exploiting tumor selective vulnerabilities with structure based drug design 
    Michael A. White
  • DNA repair inhibition and synthetic lethal opportunities
    Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts 
  • Targeting genome instability in cancer: Translating synthetic lethal biology into the clinic 
    Michael J. Zinda, Repare Therapeutics Inc., Cambridge, Massachusetts 
  • CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition* 
    Luc Furic, Peter MacCallum Cancer Centre, Melbourne, Australia 
  • DNA repair inhibition via targeting ATR activates cGAS/STING signaling, promotes anti-tumor immunity, and is a synthetic lethal strategy to augment immunotherapy response in preclinical models and clinical samples of small cell lung cancer* 
    Triparna Sen, Icahn School of Medicine at Mount Sinai, New York, New York 

Poster session A and reception
4:30-7 P.M.

Wednesday, June 12

CONTINENTAL BREAKFAST
7-8 A.M.

Plenary Session 4: Synthetic Lethality at Scale
8-10 A.M.
CME-Eligible

Session Chair: Francisca Vazquez, Broad Institute, Cambridge, Massachusetts 

  • Towards mapping the landscape of cancer vulnerabilities 
    Francisca Vazquez 
  • Synthetic lethal approaches for targeting oncogenic transcription
    Ron Firestein, Hudson Institute of Medical Research, Clayton, Australia 
  • Identifying novel therapeutic vulnerabilities in AML: From discovery to targeting
    Aniruddha Deshpande, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 
  • Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions* 
    Julia V. Milne, Peter MacCallum Cancer Centre, Melbourne, Australia 
  • Targeting mechanisms of dosage compensation to selectively kill aneuploid cancer cells* 
    Hajime Okada, Tel Aviv University, Tel Aviv, Israel 

BREAK
10-10:30 A.M.


Plenary Session 5: New Concepts in Synthetic Lethality
10:30 A.m.-12:30 p.M.
CME-Eligible

Session Chair: Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts

  • Synthetic lethal vulnerabilities in pediatric cancer
    Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Identifying and targeting cellular vulnerabilities induced by cancer aneuploidy 
    Uri Ben-David, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Emerging synthetic vulnerabilities in oncogene-driven lung cancer
    Trever G. Bivona, University of California San Francisco, San Francisco, California 
  • Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal cancers* 
    Tim Arnoldus, Netherlands Cancer Institute, Amsterdam, Netherlands 
  • CDK12 loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality* 
    Jean C. Tien, University of Michigan, Ann Arbor, Michigan 

LUNCH ON OWN
12:30-2:30 P.M.

Plenary Session 6: Synthetic Lethality of Residual Disease and Novel Drug Combinations
2:30-4:30 P.M.
CME-Eligible

Session Chair: Kris C. Wood, Duke University, Durham, North Carolina

  • Synthetic dependencies arising during tumor evolution 
    Kris C. Wood
  • Overcoming targeted therapy resistance in acute leukemia 
    Shruti Bhatt, National University of Singapore (NUS), Singapore 
  • Exploiting glutathione deficiency to identify targetable metabolic vulnerabilities in tumor cells 
    Poul H.B. Sorensen, British Columbia Cancer Research Institute and University of British Columbia, Vancouver, British Columbia, Canada 
  • Inhibiting eIF4E phosphorylation sensitizes triple-negative breast cancer to CDK4/6 inhibition* 
    Qiyun Deng, McGill University, Montreal, Quebec, Canada 
  • KAT6A/B and Menin-MLL complexes coordinately regulate estrogen receptor-driven gene expression programs in breast cancer* 
    Sarah Naomi Olsen, Dana-Farber Cancer Institute, Boston, Massachusetts 

Poster session b and reception
4:30-7 P.M.

Thursday, June 13

CONTINENTAL BREAKFAST
7-8 A.M.

Plenary Session 7: New Technologies to Discover Synthetic Lethality
8-10 A.M.
CME-Eligible

Session Chair: Francisco J. Sánchez Rivera, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts

  • Mapping environmentally induced cancer dependencies 
    Luke A. Gilbert, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 
  • High throughput evaluation of genetic variants with prime editing sensor libraries 
    Francisco J. Sánchez Rivera, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
  • Mechanisms of splicing dysregulation in cancer
    Kristen L. Karlin, Baylor College of Medicine, Houston Texas
  • Detecting pairwise and higher-order antagonistic epistatic effects among somatic cancer genotypes to discover synthetic lethality* 
    Jorge A. Alfaro-Murillo, Yale University, New Haven, Connecticut 
  • Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in KRAS mutant cancers* 
    Rand Arafeh, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 

BREAK
10-10:30 A.M.

Plenary Session 8: Translating the Next Synthetic Lethalities
10:30 A.m.-12:30 p.M.
CME-Eligible

Session Chair: Jolanta E. Grembecka, University of Michigan, Ann Arbor, Michigan 

  • Targeting epigenetic complexes in leukemia 
    Jolanta E. Grembecka
  • RNA-modifying enzyme inhibitors as synthetic lethal cancer therapeutics 
    Serena J. Silver, Accent Therapeutics, Lexington, Massachusetts 
  • Identifying and deconstructing chemical synthetic lethal interactions for the development of combinatorial therapies
    Karen M. Cichowski, Brigham and Women’s Hospital, Boston, Massachusetts
  • Discovery of selective BRM (SMARCA2) ATPase inhibitors for the treatment of BRG1(SMARCA4) mutant cancers* 
    Janice Y. Lee, Foghorn Therapeutics, Cambridge, Massachusetts 
  • Investigating vulnerabilities associated with chromosome arm aneuploidy in cancer* 
    Nadja Zhakula, Columbia University Vagelos College of Physicians and Surgeons, New York, New York 

CLOSING REMARKS
12:30 P.m.
CME-Eligible

  • Michael A. Erb, The Scripps Research Institute, La Jolla, California  
  • Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts 
  • E. Alejandro Sweet-Cordero, University of California, San Francisco, California 
  • Kris C. Wood, Duke University School of Medicine, Durham, North Carolina